Research outcomes

Bakst A, Meletiche D, Arnold R, et al. The Avandia Worldwide Awareness Registry (AWARe ) an Internet-based program for evaluation of clinical, humanistic and economic outcomes of patients with type 2 diabetes. International Society for Pharmacoeconomics and Outcomes Research Sixth Annual International Meeting. Philadelphia, Pennsylvania, 2001. 

Lewis NJ, Patwell IT, Briesacher BA. The role of insurance claims databases in drug therapy outcomes research. Pharmacoeconomics 1993 4 323-30. 

Jollis JG, Ancukiewicz M, DeLong ER, et al. Discordance of databases designed for claims payment versus clinical information systems. Implications for outcomes research. Ann Intern Med 1993 119 844-50. 

Romano PS, Roos LL, Luft HS, et al. A comparison of administrative versus clinical data coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. / Clin Epidemiol 1994 47 249-60. 

Two large trials, the Vioxx Gastrointestinal Outcomes Research (VIGOR) study and the Celecoxib Long-term Arthritis Safety Study (CLASS), compared selective COX-2 inhibitors and traditional, non-selective NSAID therapy in terms of their ability to prevent clinical PUD (i.e., symptomatic ulcers and ulcer complications). VIGOR (9-month median follow-up) demonstrated that rofecoxib (50 mg daily) therapy was significantly more efficacious than naproxen.28 The CLASS study (6-month median follow-up) found that high-dose celecoxib (400 mg twice daily) was superior to non-selective NSAID therapy (either ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily).29... 

VIGOR Vioxx Gastrointestinal Outcomes Research (study)... 

Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The schizophrenia patient outcomes research team (PORT) updated treatment recommendations 2003. Schizophr Bull 2004 30 193-217. 

In Chapter 8, professor J.L. Pinto Prades of Pompeu Fabra University and X. Badla Llach of the Health Outcomes Research Unit at Santa Creu i Sant Pau Hospital take a look at the potential contribution of economic evaluation to the regulation and control of public spending on pharmaceuticals. The authors focus on observing how economic evaluation can be used in pharmaceutical policy. To this end, they distinguish and analyse the potential this instrument has in six distinct areas the approval of pharmaceuticals by health... 

X. Bad i a Llach Consultant, Clinical Epidemiology and Public Health Department, Health Outcomes Research Unit, Sant Pau Hospital, Barcelona... 

Larry I. Palmer, LL.B., Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, Louisville, KY C.E. Reeder, Ph.D., Center for Outcomes Research and Evaluation, College of Pharmacy, University of South Carolina, Columbia, SC John A. Robertson, J.D., School of Law, University of Texas at Austin, Austin, TX Mark A. Rothstein, J.D., Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, Louisville, KY... 

In the U.S., race has been used as a proxy for a variety of physical, mental, and social dimensions. The legacy of racism still pervades society, including disparity in access to health care and in health care outcomes (see chapter by Nsiah-Jefferson, this volume). In attempting to eliminate these health disparities there have been efforts to include racial and ethnic minorities in research studies and to generate better data on racial and ethnic variations in health status. Although most policy makers and commentators believe that racial classifications in data collection and outcomes research are needed to eliminate health disparities, others believe that such policies prolong the use of a flawed concept and reify race as a pseudoscientific measure (Lee et al., 2001). 

Jane R Griffin BA(Hons) MSc, Head, Health Economics and Outcomes Research, Boehringer Ingelheim UK Ltd, Bracknell, UK... 

Epstein RS, Sherwood LM. From outcomes research to disease mauagemeut a guide for the perplexed. Auu Intern Med 1996 124 832-7. 

Rehabilitation and Outcomes Research Center NFSGVHS (ISIB)... 

Gossop M, Marsden J, Stewart D, Lehmann P, Edwards C, Wilson A Segar G (1998). Substance use, health and social problems of service users at 54 drug treatment agencies intake data from the National Treatment Outcome Research Study. British Journal of Psychiatry, 173, 166-71... 

Patterns of improvement after methadone treatment One year follow-up results from the National Treatment Outcome Research Study (NTORS). Drug and Alcohol Dependence, 60, 275-86... 

Gossop M, Marsden J, Stewart D Kidd T (2003). The National Treatment Outcome Research Study (NTORS) 4-5 year followup results. Addiction, 98, 291-303 Gossop M, Stewart D Marsden J (2006). Effectiveness of drugs and alcohol counselling during methadone treatment content, frequency, and duration of counselling and association with substance use outcomes. Addiction, 101, 404-12... 

Outcomes research is defined as studies that attempt to identify, measure, and evaluate the end results of health care services. Outcomes research may evaluate not only the clinical effects of health care services but also the economic and humanistic impact of these services. Proponents of outcomes research believe that we should measure not only the clinical and cost impacts of health care but also outcomes that take factors... 

Traditional cost-containment measures are not always consistent with improved patient care. Thus attention has turned toward demonstrating the value of health care. A full evaluation of relevant costs and consequences differentiates outcomes research from traditional cost-containment strategies. Costs are defined as the value of the resources consumed by a program or treatment alternative. Consequences are defined as the effects, outputs, and outcomes of the program or treatment alternative (Eisenberg, 1989). 

Dr. Harrison is Assistant Professor of Pharmacy Administration at the University of Oklahoma Health Sciences Center College of Pharmacy. He received a B.S. in pharmacy from the University of Missouri—Kansas City. He received an M.S. in pharmacy and a Ph.D. in pharmaceutical sciences from the University of Arizona. Dr. Harrison has experience in many areas of pharmacy operations—retail, institutional, and research. Dr. Harrison teaches courses in research design, biostatistics, and pharmacoeconomics. Dr. Harrisons research interests are in the economic analyses of pharmaceutical services, outcomes research, and strategic planning by pharmacy institutions and businesses. 

One clear aspect of the current trends in the proteomic field is the plethora of ways to achieve informational outcomes. Research developments over recent years have focused on all facets of the proteomic workflow including improvements in the comprehensiveness of analysis, efficiency of workflows, and development of specialized methods. This is aided by several mass spectrometers being available on the market that have the necessary accuracy, sensitivity, speed, and dynamic ranges. The baseline workflow for proteomics however remains essentially the same and involves a number of required steps (summarized in the succeeding text and in Figure 1) ... 

Lehman AF, Steinwachs DM. Translating research into practice The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998 24 1-10. 

In clinical practice, one caveat in considering the applicability of the outcome research is the question of whose goals are being measured. Different members of the treatment system may have different goals. The family may want specific symptom amelioration. For example, family members may want the patient to be less agitated or more able to perform the daily tasks of family life. The physician may want better medication compliance or major clinical outcomes such as reductions in psychopathology and increases in functioning. The patient may just want to be left alone. 

Vermeulen LC, Beis SJ, Cano SB. Applying outcomes research in improving the... 

International Society for Pharmacoeconomic and Outcomes Research (ISPOR)... 

---